KINASE INHIBITORS
Transcriptomic Profiling of Human Cardiac Cells Predicts Protein Kinase Inhibitor-Associated Cardiotoxicity
Using transcriptional profiles of human heart-derived primary cardiomyocyte-like cell lines treated with a list of 26 US Food and Drug Administration–approved kinase inhibitors, investigators demonstrated that acute transcriptomic changes in cell-based assays combined with drug substructures may predict a patient’s risk of kinase inhibitor–induced cardiotoxicity.
Nature Communications
